Some of the most devastating tumors develop because they have lost tumor suppressor genes. These tumors are incredibly difficult to treat and in many cases, there are simply no cures. Thanks to major progress in the sequencing of human cancers, we have identified molecular Achilles heels – i.e. the essential engines that drive these tumor genome rearrangements. Importantly, using our key epigenetic technologies Eisbach Bio can target these tumors head-on. Based on our unique screening and cellular platforms, we are developing first-in-class drugs that correct these disruptive changes within the tumor. We can do so in an extremely specific manner that spares non-cancer cells. Eisbach will beat cancer at its own game. In February 2020, Eisbach joined the world wide efforts to combat the Coronavirus pandemic and is developing inhibitors against relevant and essential SARSCoV2 proteins.